The IU School of Medicine scored a major coup five years ago when it recruited one of the nation’s top experts in the fast-growing field of regenerative medicine. But the University of Pittsburgh recruited him away this spring.
The study did not say the medications cause dementia, only that there was an association between using the drugs and a higher risk of developing dementia.
Walther will provide a one-for-one match for donors who establish endowed children’s cancer research funds at Riley Children’s Foundation, a move that could result in at least $20 million for research of new treatments of children’s cancers.
Scientists don’t yet know what causes long COVID, the catch-all term for about 200 widely varying symptoms.
A large study showed that older adults with a higher risk of dementia may be able to reduce their risk of cognitive decline by almost 50 percent by using hearing aids.
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease—after rival Leqembi. Both drugs pose a serious safety concern—brain swelling and bleeding.
The National Institutes of Health awarded the grant to the Indiana Clinical and Translational Sciences Institute, a partnership among Indiana University, Purdue University and University of Notre Dame.
Fred Cate, IU’s vice president for research, informed federal officials that the research group had “a pattern of non-compliance” and had been warned several times against using expired materials.
Five of the top 10 research studies that received the most NIH funding at the medical school were for Alzheimer’s disease or brain aging, one of the school’s top priorities.
Dr. Rachel Patzer, director of the Health Services Research Center at the Emory University School of Medicine in Atlanta, will join Regenstrief Institute on May 1.
Researchers at Indiana University School of Medicine are hoping to gain new insights into the defect, called coarctation of the aorta, or narrowing of the aorta that obstructs blood flow to vital organs.
In an amazing resurrection, teplizumab, developed by another company after Lilly trials were a letdown, is one of the hottest new drugs on the market.
The high-tech approach allows a patient recovering from substance abuse to interact with potential future versions of himself or herself.
After 15 years of coaxing and cajoling the medical community to consider a different way to do brain surgery, NICO co-founder Jim Pearson has numbers to show more surgeons and investors are buying into his vision.
Here’s how beagles being bred for research by an Indianapolis-based company became the target of the largest animal welfare seizure in the Humane Society’s history.
The money will be used to study animal models of late-onset Alzheimer’s disease as well as perform rigorous testing of potential therapeutics in animals.
Researchers in the field of colorectal cancer are hailing the study, published Sunday in the New England Journal of Medicine, as a groundbreaking development that could lead to new treatments for other cancers as well.
U.S. District Judge Norman Moon said the evidence from federal inspections shows more than 300 beagle puppies have died at the facility, which is owned by Indianapolis-based Envigo, over the last seven months of unknown causes.
Repeated federal inspections since Envigo acquired the facility have resulted in dozens of violations, including findings that dogs had received inadequate medical care and insufficient food, were housed in filthy conditions, and some had been euthanized without first receiving anesthesia.
Brooke Beier, senior vice president of commercialization at the Purdue Research Foundation, said FDA approval of the therapy is one of the most meaningful approvals ever for a Purdue-related innovation.
